Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241360
Corporate User License Price USD 10500
Corporate User License Price INR 724080
Site License Price USD 7000
Site License Price INR 482720
Request a Quote

Report Title

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H1 2017



Executive Summary

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H1 2017

Summary

According to the recently published report Interleukin 1 Receptor Type 1-Pipeline Review, H1 2017 Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

The report Interleukin 1 Receptor Type 1-Pipeline Review, H1 2017 outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Central Nervous System, Musculoskeletal Disorders and Oncology which include indications Rheumatoid Arthritis, Inflammation, Gouty Arthritis (Gout), Metastatic Breast Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Ductal Adenocarcinoma and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Overview

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Companies Involved in Therapeutics Development

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Drug Profiles

anakinra-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL-1R1 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL1R1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-130-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Dormant Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Discontinued Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Product Development Milestones

Featured News & Press Releases

May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease

Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Apr 23, 2014: First treatment for babies with ultra-rare spectrum of autoinflammatory diseases now available in UK

Dec 06, 2013: First treatment for infants with ultra-rare spectrum of autoinflammatory diseases licensed in UK

Sep 19, 2013: Swedish Orphan Biovitrum Receives CHMP Positive Opinion For Treatment Of Cryopyrin-Associated Periodic Syndrome

Jun 11, 2013: Sobi Gets FDA Approval To Manufacture Substance For Kineret With Partner Boehringer Ingelheim

Apr 18, 2013: Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease, Study Finds

Jan 23, 2013: Sobi Receives EMA Approval To Manufacture Kineret Drug Substance With Partner Boehringer Ingelheim

Jan 08, 2013: Sobi Kineret Receives FDA Approval For Treatment Of Neonatal-onset Multisystem Inflammatory Disease

Nov 19, 2012: Sobi Files To Expand Kineret Label To Include CAPS

Jul 06, 2012: Sobi Files For NOMID Indication For Kineret In US

Aug 26, 2010: Swedish Orphan Biovitrum Receives FDA Orphan Drug Designation For Kineret

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Pipeline by ProteoThera Inc, H1 2017

Pipeline by Swedish Orphan Biovitrum AB, H1 2017

Pipeline by XL-protein GmbH, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Therapeutic Products under Development, Key Players in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Therapeutics, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline Overview, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person